T
Thomas C. Luke
Researcher at Naval Medical Research Center
Publications - 39
Citations - 3190
Thomas C. Luke is an academic researcher from Naval Medical Research Center. The author has contributed to research in topics: Antibody & Virus. The author has an hindex of 17, co-authored 35 publications receiving 2860 citations. Previous affiliations of Thomas C. Luke include Silver Spring Networks & Henry M. Jackson Foundation for the Advancement of Military Medicine.
Papers
More filters
Journal ArticleDOI
Protection of Humans against Malaria by Immunization with Radiation-Attenuated Plasmodium falciparum Sporozoites
Stephen L. Hoffman,Lucy M. L. Goh,Thomas C. Luke,Imogene Schneider,Thong P. Le,Denise L. Doolan,Denise L. Doolan,John B. Sacci,John B. Sacci,Patricia de la Vega,Patricia de la Vega,Megan Dowler,Chris Paul,Daniel M. Gordon,José A. Stoute,L. W. Preston Church,Martha Sedegah,Martha Sedegah,D. Gray Heppner,W. Ripley Ballou,Thomas L. Richie +20 more
TL;DR: These results expand published findings demonstrating that immunization by exposure to thousands of mosquitoes carrying radiation-attenuated Pf sporozoites is safe and well tolerated and elicits strain-transcendent protective immunity that persists for at least 42 weeks.
Journal ArticleDOI
Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?
TL;DR: A review of 8 controlled studies published in English-language medical literature between 1918 to 1925 found that transfusion with influenza-convalescent human blood products may have reduced ri... as discussed by the authors.
Journal Article
Meta-analysis: Convalescent blood products for spanish influenza pneumonia : A future H5N1 treatment? Commentary
TL;DR: To assess the potential treatment efficacy of convalescent plasma in reducing mortality in current patients with H5N1 influenza, a review of studies from the Spanish influenza era that used influenza-convalescent human blood products to treat patients with Spanish influenza complicated by pneumonia was conducted.
Journal ArticleDOI
Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine.
TL;DR: By producing a vaccine for travelers, Sanaria will provide the infrastructure, regulatory foundation and funds necessary to speed licensure, manufacturing and deployment of the vaccine for the infants and children who need it most.
Journal ArticleDOI
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Yaseen M. Arabi,Yaseen M. Arabi,Ali H. Hajeer,Thomas C. Luke,Kanakatte Raviprakash,Hanan H. Balkhy,Hanan H. Balkhy,Hanan H. Balkhy,Sameera M. Al Johani,Abdulaziz Al-Dawood,Saad Al-Qahtani,Awad Al-Omari,Fahad Al-Hameed,Fahad Al-Hameed,Frederick G. Hayden,Frederick G. Hayden,Robert A. Fowler,Abderrezak Bouchama,Nahoko Shindo,Khalid Al-Khairy,Gail Carson,Yusri Taha,Musharaf Sadat,Mashail Alahmadi +23 more
TL;DR: Efficacy testing will be challenging because of the small pool of donors with sufficiently high antibody titers.